SunTrust Banks, Inc. reiterated their hold rating on shares of Cellectis S.A. (NASDAQ:CLLS) in a research report released on Friday. SunTrust Banks, Inc. currently has a $20.00 price target on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Nomura lowered their target price on Cellectis from $49.00 to $43.00 and set a buy rating for the company in a report on Wednesday, September 6th. Jefferies Group LLC restated a buy rating and set a $47.00 target price on shares of Cellectis in a report on Tuesday, September 26th. Zacks Investment Research lowered Cellectis from a buy rating to a hold rating in a report on Thursday, August 10th. BidaskClub lowered Cellectis from a buy rating to a hold rating in a report on Tuesday, July 25th. Finally, Wells Fargo & Company restated an outperform rating and set a $40.00 target price (up previously from $33.00) on shares of Cellectis in a report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $39.00.

Cellectis (NASDAQ CLLS) opened at 28.59 on Friday. The company’s 50-day moving average price is $28.02 and its 200-day moving average price is $28.02. Cellectis has a 52-week low of $16.09 and a 52-week high of $32.46. The company’s market cap is $1.03 billion.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/09/cellectis-s-a-clls-earns-hold-rating-from-suntrust-banks-inc.html.

Several hedge funds have recently modified their holdings of the company. Williams Jones & Associates LLC acquired a new position in shares of Cellectis during the second quarter worth $244,000. Balyasny Asset Management LLC acquired a new position in shares of Cellectis during the second quarter worth $719,000. ARK Investment Management LLC increased its position in shares of Cellectis by 79.1% during the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,784 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Cellectis by 132.1% during the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 5,435 shares in the last quarter. Finally, Sphera Funds Management LTD. increased its position in shares of Cellectis by 27.6% during the second quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after purchasing an additional 44,100 shares in the last quarter. 14.82% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Stock Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related stocks with our FREE daily email newsletter.